Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2008 2
2009 2
2010 1
2012 1
2013 4
2014 4
2016 4
2017 3
2018 2
2019 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Nonalcoholic fatty liver disease and aging: epidemiology to management.
Bertolotti M, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri S, Romagnoli D, Loria P. Bertolotti M, et al. Among authors: baldelli e. World J Gastroenterol. 2014 Oct 21;20(39):14185-204. doi: 10.3748/wjg.v20.i39.14185. World J Gastroenterol. 2014. PMID: 25339806 Free PMC article. Review.
Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.
Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A. Ballestri S, et al. Among authors: baldelli e. J Gastroenterol Hepatol. 2016 May;31(5):936-44. doi: 10.1111/jgh.13264. J Gastroenterol Hepatol. 2016. PMID: 26667191 Review.
Methodological Tools for Exploring Novel Biopharmaceutical Approaches to the Metabolic Syndrome and Related Disorders : A Commentary on: Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. A Focus on Early Phase Clinical Drug Development, Second Edition.
Lonardo A, Baldelli E. Lonardo A, et al. Among authors: baldelli e. Diabetes Ther. 2020 Apr;11(4):773-777. doi: 10.1007/s13300-020-00794-1. Epub 2020 Mar 7. Diabetes Ther. 2020. PMID: 32146692 Free PMC article. No abstract available.
Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease.
Ballestri S, Mantovani A, Baldelli E, Lugari S, Maurantonio M, Nascimbeni F, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Ballestri S, et al. Among authors: baldelli e. Diagnostics (Basel). 2021 Jan 9;11(1):98. doi: 10.3390/diagnostics11010098. Diagnostics (Basel). 2021. PMID: 33435415 Free PMC article.
25 results